Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II)

Table 2 WOMAC score before administration of treatments and 3, 6 and 12 months afterwards

WOMAC	Time	Control	BM-MSCs
WOMAC	Time	Control	Low-dose	High-dose
Pain	Baseline	5.5 (5, 6)	7.5 (5, 9)	4.5 (4, 5)
	3 months	3 (1, 3)*	3.5 (3, 7)	3 (2, 5)
	6 months	2.5 (1, 5)*	3.5 (3, 7)	3.5 (2, 5)
	12 months	2 (1, 6)	3.5 (3, 5)	2.5 (2, 4)*
Stiffness	Baseline	2 (1, 3)	4 (2, 5)	2.5 (2, 4)
	3 months	2 (1, 2)	2 (0, 4)	2 (1, 2)
	6 months	0.5 (0, 2)	1.5 (1, 3)*	2 (1, 3)
	12 months	2 (1, 2)	2 (1, 2)*	2 (1, 2)*
Function	Baseline	21 (13, 24)	26.5 (23, 32)	19 (12, 25)
	3 months	9 (7, 11)*	17.5 (8, 26)	10 (7, 18)
	6 months	7.5 (2, 13)*	18 (10, 23)	14.5 (8, 17)
	12 months	9.5 (5, 23)	17 (10, 20)	11 (9, 14)*
Overall	Baseline	29 (19, 38)	37 (32, 42)	28 (16, 34)
	3 months	12 (11, 14)*	25.5 (11, 37)	13 (11, 26)*
	6 months	10 (4, 20)*	24 (13, 31)	20 (13, 23)
	12 months	13.5 (8, 33)	21.5 (15, 26)	16.5 (12, 19)**

The values of each one of the three WOMAC subscales as well as the overall WOMAC score at baseline and 3, 6 and 12 months afterwards are presented. Data are the median (IQR) of each group. Function means physical function. *p < 0.05, **p < 0.01 with respect to the baseline value of the same group

ISSN: 1479-5876